Orano Med, a French-based biotechnology company, is in the process of opening its second US-based manufacturing facility in Brownsburg. The company plans to make a first investment of $15+ million in new laboratories and equipment to manufacture and distribute radiopharmaceuticals to treat cancer in humans.
Orano Med’s new facility will initially create a dozen of highly-skilled jobs and will assist the company in distributing this innovative cancer treatment to hospitals in the US. Future expansions are planned to cover market needs.
“This new facility is a major step of our development. It demonstrates our commitment to offer innovative 212Pb-based cancer therapies to patients in North America” said Julien Dodet, CEO of Orano Med. “Brownsburg was an obvious choice for us, and we look forward to continuing our work with the city”
“We are thrilled to welcome Orano Med to the Town of Brownsburg,” said Brownsburg Town Council President, Travis Tschaenn. “This innovative company will be an excellent addition to the community and our life science industry.”
About Orano Med
Orano Med's ambition is to develop a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells. Despite considerable advances in oncology research in recent years, high unmet needs remain in a wide variety of cancer types. Our approach, known as Targeted Alpha Therapy (TAT), has the potential to bring significant benefits where conventional therapies have failed to treat patients. Orano Med has manufacturing and R&D centers in France and in the US.